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Abstract
Background: The prevalence of trauma-related psychiatric disorders is high among refugees. Despite this, little is
known about the effect of pharmacological treatment for this patient group. The objective of the present study
was therefore to examine differences in the effects of venlafaxine and sertraline on Post-Traumatic Stress Disorder
(PTSD), depression and functional impairment in trauma-affected refugees.
Methods: The study was a randomised pragmatic trial comparing venlafaxine and sertraline in combination with
psychotherapy and social counselling. PTSD symptoms were measured on the Harvard Trauma Questionnaire – part
IV, which was the primary outcome measure. Other outcome measures included: Hopkins Symptom Check List-25
(depression and anxiety), Social Adjustment Scale – short version (social functioning), WHO-5 Well-being Index
(quality of life), Crisis Support Scale (support from social network), Sheehan Disability Scale (disability in three areas
of functioning), Hamilton Depression and Anxiety scale, the somatisation items of the Symptoms Checklist-90,
Global Assessment of Functioning scales and the summarised score of pain in four body areas rated on visual
analogue scales.
Results: Two hundred seven adult refugee patients were included in the trial (98 in the venlafaxine and 109 in the
sertraline group). Of these, 195 patients were eligible for intention-to-treat analyses. Small but significant pre-treatment
to post-treatment differences were found on the Harvard Trauma Questionnaire and a number of other ratings in both
groups. On the primary outcome measure, no difference was found in treatment effect between the sertraline and
venlafaxine group. A significant group difference was found in favour of sertraline on the Sheehan Disability Scale.
Conclusion: Sertraline had a slightly better outcome than venlafaxine on some of the secondary outcome measures,
but not on the primary outcome measure. Furthermore, a higher percentage of dropouts was found in the venlafaxine
group compared to the sertraline group. Although this could indicate that sertraline was better tolerated, which is
supported by other studies, a final conclusion on tolerability cannot be drawn from the current study due to lack of
systematic reporting of side effects.
Trial Registration: ClinicalTrials.gov NCT01569685. Registration date: 28/2/12
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Background
The prevalence of trauma-related psychiatric disorders
such as Post-Traumatic Stress Disorder (PTSD) and
depression is high among refugees [1]. Despite a rapidly
increasing amount of studies on the treatment of PTSD
in general, only few intervention studies have examined
the pharmacological treatment of trauma-affected refu-
gees [2, 3]. Therefore, clinical guidelines for the treat-
ment of PTSD are based on reviews and meta-analyses,
which mainly include studies on non-refugee PTSD
populations [4–7]. However, the results from studies on
non-refugee patients cannot be uncritically transferred
to trauma-affected refugees due to a range of differ-
ences in biomedical and psychosocial profiles as well as
trauma history [3, 8]. Survivors of civilian trauma have
often been exposed to a single traumatic event, while
refugees typically have a history of multiple and pro-
longed traumatisation [9]. Non-refugee PTSD patients
also have the advantage of generally remaining in their
habitual social, cultural and linguistic context after the
traumatic event, which is, by definition, not the case for
refugees. Consequently, trauma-affected refugees often
present with a complex mixture of psychiatric symp-
toms that goes beyond merely PTSD in combination
with psychosocial problems. Hence, they are often
described among clinicians as a hard-to-treat patient
group compared to other groups of PTSD patients [10].
Although most refugee mental health clinics offer
combined treatment programmes including both pharma-
cological treatment and psychotherapy, the evidence for
this approach is scarce. The single existent Cochrane
review on combined pharmacotherapy and psycho-
logical treatment methods in patients with PTSD [6]
identified only four studies that could be included in
the review. These studies were all conducted on fairly
small patient groups (the largest group had 65 partici-
pants for randomisation), and only one very small study
(n = 10) included refugees [11]. The authors concluded
that further research into the clinical management of
PTSD was required, including trials with larger number
of patients, using reliable and clinically meaningful out-
come measurements such as remission of PTSD and
functional outcomes. In addition, the authors called for
studies of more homogeneous patient populations.
While research on other groups of PTSD patients has
burgeoned since, intervention studies concerning
trauma-affected refugees are still limited in number and
quality, and the vast majority are on psychological
interventions only [12, 13].
Researchers at Competence Centre for Transcultural
Psychiatry (CTP), where the present study was
conducted, have prior to this study conducted research
projects on the effects of combining medical and psycho-
logical treatment as well as the effects of different types of
psychotherapy [14, 15]. In the present study, we therefore
decided to investigate the pharmacological component of
the standard combined treatment programme at CTP.
When the present study was designed, the only official
Danish guideline for the treatment of PTSD was the Danish
Medical Technology report (MTV) “The treatment and
rehabilitation of PTSD including traumatised refugees”
from 2008 [16]. It concluded that selective serotonin
reuptake inhibitors (SSRI), including the drug sertraline,
were the best-documented pharmacological treatment of
PTSD. However, both the MTV report and a Cochrane re-
view on pharmacological treatment concluded that there is
a need for more trials on patients with treatment refractory
PTSD, such as that of many refugees, because SSRI seems
to be inadequate for these patients [7, 16]. Studies of the
pharmacological treatment of PTSD on other groups of
trauma-affected patients have pointed towards the selective
Serotonine-Noradrenaline reuptake inhibitor (SNRI) venla-
faxine as an alternative treatment option [17]. Furthermore,
SNRIs are known for their analgesic effect, which we
hypothesised might be beneficial in a clinical population
where most patients suffer from chronic pain [18].
To the best of our knowledge, only one study has
investigated the use of venlafaxine in trauma-affected
refugees [19]. This open-label study, with a total number
of 32 participants (5 in venlafaxine treatment), compared
sertraline, paroxetine, and venlafaxine. All 3 antidepres-
sants produced statistically significant improvement by
week 6 in PTSD symptom severity (PTSD Symptom
Scale) while venlafaxine seemed to be less effective than
the two other drugs in reducing symptoms of depres-
sion. However, the study had quite a few methodological
problems (e.g. small groups sizes, gender imbalance
among treatment groups, short study period, no
intention-to-treat analyses), making results questionable.
Aim of the study
As stated above, venlafaxine has shown promising re-
sults in non-refugee PTSD populations, but has only
been compared to SSRIs in one small refugee study of
limited quality. On this background, we found it appro-
priate to test the effects of venlafaxine versus an SSRI in
a larger randomised trial in order to determine its effect
in trauma-affected refugees. We therefore designed a
randomised clinical trial comparing venlafaxine with ser-
traline, which was the standard choice of pharmaco-
logical treatment at CTP, where the study was
conducted. The aim of the study was to examine differ-
ences in the effectiveness of venlafaxine and sertraline in
reducing PTSD/depression symptoms and functional im-
pairments in a sample of trauma-affected refugees referred
to treatment at CTP. Based on the available literature on
non-refugee PTSD patients, as well as the effect of SNRIs
on general anxiety and depression, we hypothesised that
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venlafaxine would be as good as or better than sertraline in
reducing PTSD and depression in our sample of trauma-
affected refugees.
Methods
The trial was a randomised 2-armed pragmatic trial
using sertraline as an active control to venlafaxine. A
combination of manualised psychotherapy and social
counselling was used in both groups. The method is de-
scribed thoroughly below. Additionally, a protocol paper
has been published previously [20].
Participants
CTP is a highly specialised transcultural psychiatric out-
patient facility situated in the Capital Region of Denmark.
The largest patient group is refugees with trauma-related
mental health problems, but migrants with other mental
health problems are also treated at the clinic. Participants
in the present study were recruited from the total group
of patients who had their first appointment at CTP
between April 2012 and September 2013. Patients were
invited to 1–3 h pre-treatment interviews with one of the
clinic’s medical doctors in order to obtain psychiatric,
medical, and trauma history, and to evaluate whether the
patient belonged to the study target group and was moti-
vated for treatment. If the patient fulfilled all inclusion but
no exclusion criteria and gave written informed consent,
the patient was included in the study and randomised to
one of the two treatment groups. Inclusion criteria were:
being a refugee or family-reunified to a refugee, being
18 years or above, having a history of at least one severe
psychological trauma, fulfilling the diagnosis of PTSD
and/or depression according to ICD-10 research criteria
[21], being motivated for treatment, and giving informed
consent to participate in the study. Exclusion criteria were:
an ICD-10 F2x (schizophrenia, schizotypal and delusional
disorders) or bipolar diagnosis, current abuse of drugs or
alcohol, in need of acute admission to a psychiatric
hospital, being pregnant or breastfeeding or being a
woman in the reproductive age with a wish to conceive
during the project period.
The diagnoses of PTSD, depression and enduring
personality change after catastrophic experience were
determined through a clinical interview by one of the
CTP doctors who entered ICD-10 criteria for each of
the diagnoses into a diagnostic algorithm. Psychotic and
bipolar disorders were excluded using relevant parts of
the SCAN interview and all doctors performing these
interviews were certified SCAN raters. Trauma-related
psychotic symptoms are relatively common in this pa-
tient group and were therefore not among the exclusion
criteria [22, 23].
Patients were systematically inquired about their use
of drugs and alcohol. Objective measures, such as an
alcohol breath tester, were available but only used in
cases where the clinician suspected that the patient was
dishonest about current abuse.
Patients who fulfilled the inclusion criteria, but did not
wish to participate in the study, were offered the clinic’s
treatment as usual (TAU), which was similar to the
treatment provided to the sertraline group. If patients
did not want pharmacological treatment, it was still pos-
sible to receive treatment but, for obvious reasons, not
possible to participate in the study.
From 1 April 2012 until 15 September 2013, a total of
406 patients were screened for the trial, out of which
207 patients fulfilled all inclusion and no exlusion
criteria and gave informed consent to participate in the
study. The participants were randomised upon intake as
described above – 98 to the venlafaxine group and 109
to the sertraline group. The last patient completed treat-
ment in September 2014. Participants’ flow through the
trial is depicted in Fig. 1.
Randomisation and blinding
Randomisation by envelopes was performed, stratified by
gender and level of severity of PTSD symptoms on the
basis of Harvard Trauma Questionnaire (HTQ) score
(above or below 3.2). A computer generated list was
made by the Department of Biostatistics at the Univer-
sity of Copenhagen which was not otherwise involved in
the trial. Consecutively numbered envelopes was sealed
and these envelopes were administered by a group of
secretaries at the central administration at Mental
Health Centre Ballerup who had no other contact with
the clinical staff at CTP during the study. Once a patient
was included in the study, the doctor responsible for the
inclusion phoned these secretaries and was informed of
the group allocation.
Neither doctors nor patients were blinded in this
study, while the raters administering the Hamilton
Depression Scale (HAM-D) and the Hamilton Anxiety
Scale (HAM-A) (please see below) were blinded to the
time of the interview (so that the raters did not know
whether it was a pre-treatment or post-treatment inter-
view) and to the intervention group. A team of medical
students, trained at CTP, administered the Hamilton
scales. Inter-rater reliability was maximised by group
ratings every 6–8 weeks.
The intervention
The study compared a venlafaxine group with a sertra-
line group. For both groups, the treatment programme
was planned to last 6–7 months. Patients in both groups
were offered a total of 10 sessions with a psychiatrist/
medical doctor (hereinafter referred to as doctor) and 16
sessions with a psychologist. All patients were offered
one session with a social worker at the beginning and
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one at the end of the treatment programme, and more
of such sessions were provided during the treatment
programme if needed. Furthermore, it was optional for
the patients to participate in group sessions with the
social worker once a month. For all patients, the exact
number of consultations as well as theme(s) of the
session were registered at each consultation using a tick
box sheet in accordance with the Treatment and
Research Integrated Model (TRIM) used at CTP [24].
The venlafaxine group
Venlafaxine was given as slow-release tablets. The start
dosage was 37.5–75 mg/day. For the first six weeks (phase
1), doctors aimed to see patients weekly and gradually in-
creased the dosage by 37.5–75 mg at each consultation if
tolerated by the patient. During phase 2 (the remaining
part of the treatment programme), patients met with their
doctor approximately once a month. If side effects did not
prohibit, dosage was increased at these visits. The dosage
could be increased up to the maximum recommended
daily dosage of 375 mg/day.
The sertraline group
At the time of the study, sertraline was the first-line
pharmacological treatment at CTP. The recommended
start dosage was 25–50 mg. Like the venlafaxine group,
patients in the sertraline group met with the doctor
once a week during phase 1 and once a month during
phase 2. Sertraline dosage was increased gradually by
25–50 mg per week for the first 6 weeks, and then ad-
justed once a month to a maximum of 200 mg/day.
Patients in both groups were instructed to take the
prescribed medicine daily unless intolerable side effects
occurred, in which case they should contact their doctor
at CTP immediately. In addition to the trial medicine, all
patients were offered supplementary treatment with
mianserin if they suffered from severe sleep distur-
bances, which is the case for many patients with PTSD.
Although no patients with a psychotic disorder were in-
cluded in the study, some patients did suffer from
trauma-related psychotic symptoms. If treatment with
antipsychotic drugs was necessary from a clinical point
of view, the patient would either continue with the anti-
psychotic treatment he/she was already receiving or start
treatment with perphenazine. However, during the study
period, perphenazine was taken off the Danish pharma-
ceutical market and we therefore decided to replace it
with quetiapine in accordance with the current recom-
mendation for first-line antipsychotic treatment in the
clinical guidelines for the Capital Region of Denmark.
However, CTP kept a stock of perphenazine for almost
the entire remaining study period, and it is likely that
Fig. 1 Participants flow through the trial
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only a very limited number of patients were affected by
this change.
Whenever possible, patients were gradually taken off any
other psychopharmacological treatments they received
when entering the study. All these psychotropics were
given free of charge by the clinic to the patient during
the entire treatment programme regardless of whether
they participated in the study or not.
Psychotherapeutic treatment
Patients in both groups were offered 16 sessions of
individual manual-based flexible cognitive behavioural
therapy (CBT). The manual, developed by the psychol-
ogists employed at CTP, was based on the available
literature and the experiences with the three previous
manuals used during the prior randomised trials at the
clinic [14, 15]. It set out flexible CBT, including elements
from trauma-focused cognitive behavioural therapy (TF-
CBT), acceptance and commitment therapy (ACT), stress
management and mindfulness. All methods were adapted
to fit the transcultural patient group [25].
Compliance
Compliance is one of the major issues in most pharma-
ceutical studies with refugees and immigrants. Despite
many attempts to secure compliance (written instruc-
tions in the patient’s own language, medical cards etc.),
it was expected that many patients would have periods
of poor compliance when, for example, running out of
medicine, misunderstanding the dose or terminating
pharmacological treatment without consulting the staff
at the clinic.
Since frequent collection of blood samples could have a
negative effect on the mental health of a patient group
with a substantial amount of torture survivors, compliance
was instead measured by pill count at each consultation
with the doctor. If patients forgot to bring their medica-
tion to the consultation, this was noted in the patient file,
and days of compliance were then calculated as the med-
ical possession ratio (the number of days for which the
patients had sufficient medicine) during the data manage-
ment phase of the study. If patients had at least eight con-
secutive weeks of pharmacological compliance during the
study period, they were defined as completers of the
pharmacological part of the treatment programme.
Measurements
The treatment outcome was measured by a combination
of non-blinded self-report ratings and blinded observer
ratings. The primary outcome measure was self-reported
PTSD symptoms assessed using part IV of the Harvard
Trauma Questionnaire (HTQ), which has been developed
primarily for trauma-affected refugees and validated in
several languages and settings [26, 27]. Secondary outcome
measures included depression and anxiety symptoms mea-
sured on the Hopkins Symptom Check List-25 (HSCL-25)
[28] and on the Hamilton Depression and Anxiety Ratings
Scales (HAM-D and HAM-A) [29], social functioning mea-
sured on the Social Adjustment Scale Self Report (SAS-SR)
short version [30], social support assessed on the Crisis
Support Scale (CSS) [31], level of functioning assessed on
the Sheehan Disability Scale (SDS) [32], quality of life
assessed on the WHO-Five Well-being Index (WHO-5)
[33], the somatisation scale of SCL-90, the mean score of
pain in four different body areas rated on Visual Analogue
Scales (VAS) and levels of symptoms and functioning
assessed on the Global Assessment of Functioning (GAF)
[34]. These measures were all self-report ratings except the
GAF-scores, which were completed by the doctor in charge
of the treatment and the HAM-D and HAM-A, which
were completed by blinded assessors as described above.
Based on our experience with the patient group, we esti-
mated that the majority of the study participants would be
out of job [14]. We therefore used a modified version of the
SDS where the wording of the first item was ‘work/daily
tasks’ (this version had been used in previous studies at
CTP). For the same reason, we chose the SAS-SR over
other rating scales of social function, since the phrasing of
the questions similarly takes patients without jobs into
consideration.
All self-report ratings were available in 5 languages:
Danish, English, Farsi, Bosnian, and Arabic. Some of
the ratings were available in Russian as well. Apart
from SAS-SR short version and CSS, all outcome mea-
sures were used in previous randomised clinical trials
at the clinic and were translated and implemented
before this study commenced. In cases without a vali-
dated translation, a translated version was produced by
standard translation and back-translation procedures.
Whenever needed during ratings or treatment sessions,
patients were assisted by a professional interpreter if
they wished so.
Patients were asked to complete most self-report rat-
ings three times during the study: at the pre-treatment
interview (pre-treatment rating), right before starting
psychotherapy, and at the end of the treatment
programme (post-treatment rating). However, as a rela-
tively high number of patients did not complete the
second rating before starting psychotherapy, only the
pre- and post-treatment ratings were used in the ana-
lyses (please see the data management section below).
If the pre-treatment interview was conducted more
than two months before the patient’s first consultation
with a doctor, a new rating was conducted at the first
treatment session with the doctor, and this new rating
was then used as the pre-treatment rating. SAS-SR and
CSS were completed twice during the study: at the first
and at the last consultation with the social worker. The
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blinded Hamilton interviews were also carried out twice:
at the beginning and at the end of the treatment
programme. Patients who terminated the treatment
programme before time were encouraged to complete
the same post-treatment questionnaires as those who
completed the full treatment programme.
Reliability
Reliability of the ratings used in the study was generally
high. Cronbach’s alpha was calculated for all ratings that
included more than one item and ranged between 0.69
(CSS) and 0.90 (HSCL-25). For the primary outcome
measure, the HTQ, Cronbach’s alpha was 0.79.
Data management and statistics
Data was entered into the clinic’s Access database twice
and discrepancies corrected according to the case record
files. Rating scale scores were recorded as missing if
more than half of the scale items were unanswered.
Analyses were performed using Stata 14.
Pre-treatment data and descriptive data on the treat-
ment provided were analysed for group differences using
chi-square and t tests. Cronbach’s alpha was determined
for all pre-treatment ratings. Differences between post-
treatment and pre-treatment ratings were analysed using
a mixed model, which for each outcome included inter-
vention group, rating time (pre-treatment vs. post-
treatment) and the interaction between intervention
group and time as predictors. Using Stata’s “margins’
and “contrast” commands, the model made it possible to
estimate pre- and post-treatment group means, to test
group differences in pre- and post-treatment ratings sep-
arately; differences between pre- and post-treatment rat-
ings in each group; and group differences in differences
between pre- and post-treatment ratings (corresponding
to the interaction between intervention group and rating
time). This analysis was conducted on both a reduced
sample, consisting of patients with complete data on
both pre- and post-treatment ratings, and on an
intention-to-treat sample, which included all patients
with pre-treatment ratings. Pre-post-treatment differ-
ences are often correlated with pre-treatment scores,
and, consequently, differences between the sertraline
and venlafaxine groups were also analysed with regres-
sion models that included the pre-treatment scores on
each rating scale and an indicator variable for treatment
group as predictor and the score on the rating scale as
outcome. To conduct intention-to-treat analyses, the
regression analyses were conducted using Full Informa-
tion Maximum Likelihood (FIML), which incorporates
all available information including pre-treatment scores
for patients without post-treatment scores. The struc-
tural equation modeling procedure “sem” in Stata 14
was used to conduct these analyses. Both the mixed
model and the regression models were conducted with
robust standard errors.
Results
Characteristics of participants
Pre-treatment characteristics for the two groups, including
sociodemographic data, trauma history, and psychiatric
diagnoses, are illustrated in Table 1. Almost 99 % of the
patients had comorbid depression and a little more than
40 % were diagnosed with enduring personality change
after catastrophic experience (F.62.0). Another comorbid
psychiatric disorder was registered for almost 12 %, but this
disorder was not neccarily specified in accordance with
ICD-10 in the patient files. The vast majority of the diagno-
ses were anxiety disorders, with generalised anxiety (F.41.1)
being the most frequent. None of the analysed variables
differed significantly between groups, although there was a
borderline significant difference in distribution of torture
survivors (p = 0.054). Just over 60 % of the patients required
an interpreter for treatment sessions (61 % for medical doc-
tor sessions and 63 % for psychologist sessions).
Attrition and compliance with treatment programme
Twelve patients (seven patients in the venlafaxine group
and five in the sertraline group) were excluded from the
study: four due to pregnancy, two due to hospital admis-
sions (one to a psychiatric and one to a somatic ward),
one was wrongly included in the study (was not a refugee),
one moved to another part of Denmark, two changed
their minds about initiating treatment at CTP and two
withdrew informed consent. Accordingly, 195 patients
(94.2 %) were available for intention-to-treat analyses.
A total group of 156 patients (75.4 %) completed mini-
mum 8 weeks of pharmacological treatment in accord-
ance with the group to which they were randomised (68
in the venlafaxine group and 88 in the sertraline group).
The majority of the non-completers took the allocated
antidepressants during part of the treatment programme,
but either stopped before 8 weeks or took their medica-
tion irregularly during large parts of the treatment
programme. Reasons reported for not completing
8 weeks of pharmacological treatment included dropping
out of the CTP treatment programme (n = 17), side
effects to medication (n = 10), not wanting pharmaco-
logical treatment after all (n = 3) or not wanting to
change present medication to allocated antidepressant
(n = 1). No reasons were reported for the remaining
non-completers (n = 8).
Pharmacological side effects
As mild side effects are common for both venlafaxine
and sertraline, it was expected that many patients
would have side effects during parts of the study, which
was also the case according to the clinicians’ reports.
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Changes in the patients’ physical condition were registered
at each medical doctor session, but only unexpected or
serious events/side effects were systematically collected
and reported to the ethics committee and the Danish
Medicines Agency, in accordance with Danish legislation
at the time being.
Only 10 patients terminated their pharmacological
treatment because of reported side effects. However, as
17 patients did drop out of the entire treatment
programme without a specified reason and no reasons
were reported for an additional eight non-completers,
the actual number of patients with intolerable side
effects could have been higher. Three patients had to
switch drugs during the trial: two did not tolerate
venlafaxine but did tolerate sertraline and one only toler-
ated venlafaxine. These three patients were kept in the
group to which they were randomised during the
intention-to-treat analyses.
Treatment
Patients received a mean number of eight medical doctor
sessions, 10 psychologist sessions and two social worker
sessions with no significant differences between the two
groups. Only 29 patients (14 in the venlafaxine group and
15 in the sertraline group) participated in at least one
group session with a social worker.
Mean treatment length was 6.3 months. Mean dose of
sertraline was 96.21 mg and mean dose of venlafaxine
was 125.41 mg. Ten patients in the venlafaxine group
received a mean dose larger than 225 mg. A total num-
ber of 63 patients (69.23 %) in the venlafaxine group
and 80 patients (76.92 %) in the sertraline group
received add-on mianserin at some point during the
study, with a mean dose of 13.57 mg (no significant
group difference). A total of 19 patients in the venlafax-
ine group (20.88 %) and 23 patients in the sertraline
group (22.12 %) received treatment with antipsychotics
at some point, although many of these were phased out
during the study.
Outcomes
Pre-treatment and post-treatment ratings
The primary outcome measure HTQ was completed
both at pre-treatment and post-treatment by 154
patients. With regard to the other ratings, the number of
patients who had completed both pre-treatment and
post-treatment ratings ranged between 123 (GAF-F) and
158 (HAM-D).
Table 2 presents the results of the mixed model
intention-to-treat analysis (the results of the reduced
sample are presented in a Additional file 1: Table S1).
For the pre-treatment ratings, the two groups only
differed significantly on the SDS score and there were
no significant group differences on the post-treatment
scores. The table also shows the differences between
pre-treatment and post-treatment ratings for each group
and the group differences with respect to the difference
between pre- and post-treatment ratings.
The table shows small but significant improvements in
both groups on the primary outcome measure HTQ as
well as on a number of other ratings: HSCL-25, SAS-SR,
GAF-S and GAF-F. On the blinded Hamilton ratings,
the CSS, the SCL-90 and the VAS pain scale, no signifi-
cant changes were found in either of the groups. On the
WHO-5, we found a significant improvement in the
sertraline group only, and the difference between the
two groups was reflected in a significant interaction
between group and rating time (p = 0.04). This pattern
Table 1 Pre-treatment characteristics for the study population
Pre-treatment characteristics All
(n = 207)a
Venlafaxine
(n = 98)a
Sertraline
(n = 109)a
N(%)
Demographic information
Male gender 124 (60.2) 61 (62.2) 63 (58.3)
Country of origin
Ex-Yugoslavia 20 (9.7) 11 (11.2) 9 (8.3)
Iran 28 (13.6) 13 (13.3) 15 (13.9)
Iraq 71 (34.5) 34 (34.7) 37 (34.3)
Afghanistan 28 (13.6) 10 (10.2) 18 (16.7)
Lebanon 26 (12.6) 12 (12.2) 14 (13.0)
Other 33 (16.2) 18 (18.4) 15 (13.9)
Diagnosis (ICD-10) in addition to PTSD
Depression 204 (98.6) 96 (97.96) 108 (99.08)
Enduring personality change
after catastrophic experience
(F.62.0)
80 (40.8) 38 (41.30) 42 (40.38)
Other psychiatric disorder 24 (11.7) 12 (12.24) 12 (11.11)
Trauma history
Imprisonment 110 (53.4) 57 (58.8) 53 (48.6)
Torture** 99 (48.1) 54 (55.1) 45 (41.7)
Refugee camp 52 (25.7) 22 (22.9) 30 (27.5)
Psychosocial status
Education >10 years from home
country
98 (50.8) 50 (53.2) 48 (48.5)
Presently employed/studying 14 (7.0) 7 (7.3) 7 (6.8)
Living alone all the time 51 (25.8) 21 (21.9) 30 (29.4)
Have got children less
than 18 years old
137 (68.8) 68 (70.8) 69 (67.0)
Mean(SD)
Age 43.7 (9.7) 43.2 (9.6) 44.0 (9.7)
Years since arrival in Denmark 14.6 (7.3) 14.1 (7.1) 15.1 (7.4)
Pre-treatment characteristics for the venlafaxine and sertraline groups
N Number of study participants, SD Standard deviation
** Group difference borderline significant, p = 0.054
aNot all variables available for the entire patient group
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Table 2 Score differences between pre-treatment and post-treatment ratings
Rating Groups and differences Mean pre-treatment score (SE) Mean post-treatment score (SE) Difference (SE) P-value Effect size
Symptoms self-ratings
HTQ Sertraline 3.24 (0.04) 3.02 (0.06) 0.22 (0.06) <0.01** 0.54
Venlafaxine 3.18 (0.05) 3.05 (0.06) 0.13 (0.06) 0.02* 0.32
Difference 0.06 (0.06) −0.03 (0.09) 0.09 (0.08) 0.27 0.22
HSCL-25 Sertraline 3.03 (0. 05) 2.85 (0.07) 0.18 (0.07) <0.01** 0.39
Venlafaxine 3.04 (0.05) 2.94 (0.06) 0.10 (0.05) 0.05* 0.22
Difference −0.01 (0.07) −0.09 (0.09) 0.08 (0.09) 0.37 0.17
SCL-90 Sertraline 2.40 (0.08) 2.35 (0.10) 0.05 (0.10) 0.64 0.06
Venlafaxine 2.50 (0.08) 2.53 (0.09) −0.03 (0.07) 0.69 0.04
Difference −0.10 (0.10) −0.18 (0.13) 0.08 (0.12) 0.54 0.10
VAS Sertraline 6.38 (0.24) 6.17 (0.28) 0.21 (0.26) 0.43 0.26
Venlafaxine 6.61 (0.24) 6.68 (0.24) −0.07 (0.20) 0.72 0.03
Difference −0.23 (0.34) −0.51 (0.36) 0.28 (0.33) 0.40 0.12
Life quality/level of functioning self-ratings
WHO-5 Sertraline 12.73 (1.36) 22.21 (2.67) −9.48 (2.42) <0.01** 0.65
Venlafaxine 15.00 (1.64) 17.75 (2.24) −2.75 (2.16) 0.20 0.19
Difference −2.27 (2.13) 4.46 (3.49) 6.73 (3.24) 0.04* 0.47
SDS Sertraline 24.65 (0.53) 21.81 (0.88) 2.84 (0.85) <0.01** 0.48
Venlafaxine 22.71 (0.69) 23.20 (0.79) −0.49 (0.86) 0.57 0.08
Difference 1.93 (0.87)* −1.39 (1.17) 3.32 (1.21) <0.01** 0.56
SAS-SR Sertraline 2.93. (0.07) 2.68 (0.08) 0.25 (0.07) <0.01** 0.36
Venlafaxine 2.96 (0.07) 2.80 (0.0.08) 0.16 (0.08) 0.04* 0.23
Difference −0.03 (0.10) −0.12 (0.11) 0.09 (0.11) 0.39 0.13
CSS Sertraline 22.34 (0.89) 22.89 (0.80) −0.55 (0.79) 0.48 0.07
Venlafaxine 22.14 (0.76) 22.40 (0.79) −0.26 (0.73) 0.72 0.03
Difference 0.20 (1.17) 0.49 (1.13) 0.29 (1.07) 0.79 0.04
Observer ratings
HAM-D Sertraline 23.69 (0.55) 22.33 (0.85) 1.36 (0.79) 0.08 0.24
Venlafaxine 23.69 (0.62) 22.46 (0.89) 1.23 (0.82) 0.13 0.22
Difference 0.00 (0.83) −0.13 (1.23) 0.13 (1.14) 0.91 0.02
HAM-A Sertraline 26.74 (0.68) 26.41 (1.04) 0.33 (0.97) 0.73 0.05
Venlafaxine 27.14 (0.72) 26.05 (1.05) 1.09 (1.00) 0.28 0.16
Difference −0.40 (0.99) 0.36 (1.49) −0.76 (1.39) 0.58 0.11
GAF-S Sertraline 47.43 (0.57) 51.33 (0.93) −3.90 (0.79) <0.01** 0.68
Venlafaxine 48.14 (0.61) 51.82 (0.94) −3.68 (1.03) <0.01** 0.64
Difference −0.70 (0.83) −0.48 (1.32) 0.22 (1.29) 0.86 0.04
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was even clearer on the Sheehan Disability Scale, where we
found a significant improvement in the sertraline group,
but a non-significant deterioration in the venlafaxine
group. This group difference was reflected in a significant
interaction between group and rating time (p < 0.01).
Differences in effects between groups
Table 3 illustrates the differences between the sertraline
group and the venlafaxine group in the intention-to-
treat sample analysed with Full Information Maximum
Likelihood, which means that we were able to use data
from all 195 patients included in the intention-to-treat
sample. No significant treatment difference was found
on the primary outcome measures. On the other
outcome measures, we found a significant group differ-
ence on SDS only and borderline significant differences
between the treatment groups on WHO-5 (p = 0.07).
These group differences were both in favour of sertraline
and in line with the results presented in Table 2.
Discussion
Our study is the largest study ever comparing different
pharmacological treatment options for trauma-related
psychiatric disorders among refugees. We found no sta-
tistically significant group differences on the primary or
secondary outcome measures except a significant differ-
ence on the SDS (level of functioning) and on the WHO-5
(quality of life), but the latter only marginally significant
Table 2 Score differences between pre-treatment and post-treatment ratings (Continued)
GAF-F Sertraline 48.37 (0.68) 50.28 (0.92) −1.91 (0.79) 0.02* 0.29
Venlafaxine 49.04 (0.68) 51.91 (0.96) −2.87 (0.89) <0.01** 0.43
Difference −0.67 (0.97) −1.63 (1.33) 0.96 (1.19) 0.42 0.06
HAM = 0–4 (0 best score), GAF = 0–100 (100 best score), WHO-5 = 0–100 (100 best score), SDS = 0–30 (0 best score), SAS-SR = 1–5 (1 best score), CSS = 1–7 (7 best),
HTQ, HSCL-25, SCL = 1–4 (1 best score), VAS = 0–10 (0 best score)
WHO-5 WHO-Five Well-being Index, SDS Sheehan Disability scale, SAS-SR Social Adjustment Scale - Self Report, CSS Crisis Support Scale, HTQ Harvard Trauma
Questionnaire, HSCL-25 Hopkins Symptom Checklist-25, SCL-90 Symptom Checklist-90, VAS Visual Analogue Scale (for pain), HAM-A Hamilton Anxiety scale and
HAM-D Hamilton Depression scale, GAF Global Assessment of Functioning (S = symptom score and F = functioning score)
Overview over pre-treatment and post-treatment rating scores for the intention-to-treat sample. In the right column the p-values refer to the significance of
differences between pre- and post-treatment ratings in each group and the significance of group differences in the difference between pre- and post treatment
ratings (corresponding to the interaction between intervention group and rating time). Based on the mixed model for the full sample group differences at the
pre- and post-treatment assessments were estimated as simple main effects and so were the pre-post treatment differences for each intervention group. The
group difference in pre-post treatment differences corresponds to the interaction coefficient in mixed model. SE = Robust standard error Effect size: The effect size
calculated as the pre-post score difference/the baseline standard deviation
* = statistically significant (p = 0.05 or below), ** = higly statistical significant (p = 0.01 or below)
Bold = Improvement, Italic = Deterioration
Table 3 Regression coefficients for group differences at follow up
Rating Regression coeffiecient, B (95 % CI) Beta-cofficient SE Z P
Adjusted for pre-treatment rating scores
HTQ 0.07 (−0.09 – 0.22) 0.06 0.08 0.84 0.40
HSCL-25 0.07 (−0.10 – 0.23) 0.05 0.08 0.80 0.42
SCL 0.12 (−0.12 – 0.35) 0.07 0.12 1.03 0.31
SDS 2.31 (0.10 – 4.52) 0.16 1.13 2.05 0.04*
WHO-5 −5.79 (−12.05 – 0.46) −0.13 3.19 −1.82 0.07*
VAS 0.36 (−0.23 – 0.96) 0.08 0.30 1.20 0.23
SAS-SR 0.10 (−0.09 – 0.29) 0.07 0.10 1.06 0.29
CSS −0.35 (−2.18 - 1.47) −0.02 0.93 −0.35 0.71
GAF-F 1.22 (−1.03 – 3.47) 0.08 1.15 1.07 0.29
GAF-S 0.06 (−2.37 – 2.48) 0.00 1.24 0.04 0.96
HAM-D 0.19 (−1.94 – 2.33) 0.01 1.09 0.18 0.86
HAM-A −0.57 (−3.19 – 2.04) −0.03 1.34 −0.43 0.67
Post-treatment differences between the venlafaxine and sertraline groups for the intention-to-treat sample
CSS Crisis Support Scale, GAF Global Assessment of Functioning, HAM-A Hamilton Anxiety scale, HAM-D Hamilton Depression scale, HTQ Harvard Trauma
Questionnaire, HSCL-25 Hopkins Symptom Checklist-25, SAS-SR Social Adjustment Scale - Self Report, SCL-90 Symptom Checklist-90, SDS Sheehan Disability scale,
VAS Visual Analogue Scale, WHO-5 WHO-Five Well-being Index, B Regression coeffiecient, CI Confidence interval, Z Z-value SE Robust standard error of the regres-
sion coeffiecient, B, P P-value for the regression coeffiecient, B
Bold: In favor of sertraline
Italic: In favor of venlafaxine
Bold and *: Statistically significant
*: Marginally significant
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when post-treatment scores were adjusted in relation to
pre-treatment scores. In contrast to our hypothesis, the
detected differences were in favour of sertraline. The
relatively large number of outcome measures in this
study implies a risk of random findings of significant
group differences. This will statistically be the case for
5 % of the findings when a significance level of p = 0.05
is applied and may be the case for the few significant
findings in our study. However, in spite of the few sig-
nificant group differences, we found, throughout the
ratings, a fairly consistent tendency to somewhat better
outcome in the sertraline group, which makes it less
likely that the findings are random.
The most recent meta-analysis on mixed groups of PTSD
patients found the evidence for the effect of venlafaxine to
be superior to that of sertraline [35]. Similarly, a meta-
analysis from 2012 found a larger effect of venlafaxine on
the Clinician-Administered PTSD Scale (CAPS) [36]. The
fact that our study was not able to replicate this finding
could be due to a range of factors. One likely explanation is
the relatively low mean dose of venlafaxine that the patients
received in the present study. Venlafaxine’s effect on nor-
adrenaline reuptake is dose-dependent, starting on doses of
around 225 mg daily. When the daily dose is lower, it acts
on serotonin reuptake only, like a common SSRI [36, 37].
Other studies have furthermore suggested that there are
biological differences between Caucasians and people from
the Middle Eastern areas, including the percentage of fast
metabolisers being substantially larger among Middle
Eastern patients [8]. It is, however, also a possibility
that the true differences between the effectiveness of
sertraline and venlafaxine in treating PTSD are rather
small as another meta-analysis from 2013 found only
little difference in effect sizes [4].
During the study, changes in the patients’ physical condi-
tion were recorded at each medical doctor session, but only
unexpected or serious events/side effects were systematic-
ally collected and reported. Therefore, we cannot for cer-
tain conclude if side effects occurred more frequently in the
venlafaxine group than in the sertraline group. However,
the fact that we ended up with a relatively low dose of ven-
lafaxine, even though we aimed for maximum doses, might
suggest that the acceptability of sertraline was larger than
that of venlafaxine in the population of the present study.
This was also the case in the only other RCT comparing
sertraline and venlafaxine in trauma-affected refugees [19],
in which the number of drop outs were higher in the venla-
faxine group and in line with findings from studies with
other psychiatric patient groups [38].
Overall we found some small but significant differences
between pre-treatment and post-treatment ratings in both
groups on the primary and most of the secondary out-
come measures. As the patient sample in the present
study compromised severely trauma-affected refugees
who were referred to a specialised clinic, the rather small
improvements are not surprising. Furthermore, as the
pre- to post-treatment improvements presented are means
of the 195 patients included in the analyses, some patients
will definitely get a much larger improvement. Although
out of scope of the present paper, predictors of positive
treatment outcomes are important to examine in order to
further improve the treatment. Using the present sample,
these predictors have been analysed in a recently pub-
lished paper [39].
The study design, with no placebo or control group,
does not allow us to conclude whether the improvements
detected are due to an effect of the treatment programme
provided. However, a previous study conducted at CTP
found a small but significant effect of sertraline on depres-
sion compared to waitlist controls, and it therefore seems
likely that at least part of the change is due to the pharma-
cological treatment in the present study too [14].
As a high percentage of patients in both groups were
taking a small dose of mianserin during parts of the study,
the sleep enhancing effect of mianserin might contribute
to the overall change. If we assume that the change we
found between pre-treatment and post-treatment ratings
on the majority of measures is partly due to the pharma-
cological treatment, it might very well be the effect of the
combination of mianserin and the investigated antidepres-
sants rather than sertraline or venlafaxine alone.
Around 21 % of the total study population took anti-
psychotic medication at some point during the trial.
Although there was no significant group difference in
the use of antipsychotics, one cannot rule out that a pos-
sible effect of antipsychotics on the patients’ PTSD
might have hidden differences in effects between the
two groups due to a ceiling effect on brain receptors.
The general small pre-to post-treatment changes in both
groups do, however, make this less likely.
The duration of the study was six months, during
which the patients gradually started pharmacological
treatment. This meant that patients usually received
antidepressants for substantially shorter time when eval-
uated. It is therefore possible that part of the treatment
effect only can be observed after a longer post-treatment
period. For this reason, patients in the present study will be
invited to follow-up interviews and rating-completion 6
and 18 months after termination of treatment programme.
Limitations and strengths
Our trial has certain limitations. Blinded observer rat-
ings were carried out, but neither patients nor clinical
staff members were blinded to treatment allocations.
This was decided by an expert team of doctors at CTP
having a substantial amount of experience with, and
knowledge about, trauma-affected refugees. Due to the
nature of the trauma previously experienced by many
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of the patients (torture experiences) and the subsequent
complex PTSD with suspicion as a key feature, the
clinicians found it likely that a majority of the patients
would decline participation if blinded. A substantial
selection bias would have been very unfortunate in this
study since we were aiming to get a population and a
set-up that were to a large extent, comparable with any
other clinic in the field, making the study results easy
to implement elsewhere. In the current study design,
where most outcome measures were self-report ratings,
the gains of blinding would have been limited. In
combination with the risk of greater selection bias, this
was the basis for the current pragmatic design where
blinded observer ratings were chosen as recommended
by authors of similar studies in the field [19].
The study did not include a waitlist or placebo control
group due to both pragmatic and ethical considerations.
The primary aim of the present study was to compare
the effect of the two types of antidepressants, not to
measure the overall effect of the treatment programme.
Since another study at the clinic, which included a wait-
list control group, had recently been completed [14], we
found it less important to include a waitlist control
group in the present study and found it more important
to achieve larger samples in the pharmacological treat-
ment groups. However, in light of the relatively small
effect sizes found in the waitlist control group trial [14]
and the little evidence of differential effects of the types
of pharmacological treatment, it would have been
advantageous being able to compare the effects of the
two pharmacological treatments with a waitlist control
group. Since there was not a natural waiting list at the
time of the present study it might however, have been
ethically questionable to prevent participants in the
study from immediate treatment.
Pill count was used to determine compliance. This is nat-
urally a less secure method than blood tests as patients
could potentially hide poor compliance from the clinical
staff by throwing away their medication. However, we
chose the present method based on the assumption that
some patients would find the frequent collection of blood
samples unacceptable due to their trauma history. Blood
tests as compliance measures do however hold some ad-
vantages over pill counts. They are an objective measure of
whether the patients are taking the medication and also
provide some indication of whether the blood level of the
medication is within a therapeutic range. This is especially
relevant in non-western populations where percentages of
fast drug metabolisers have been found to differ from west-
ern populations. In the present study, this difference could
potentially have influenced the efficacy of the pharmaco-
logical agents investigated, and it would therefore have
been beneficial to know whether blood levels of the anti-
depressant agents were within the therapeutic range.
Questions of validity and reliability of the ratings are
important when it comes to measuring treatment out-
comes in refugee populations with diverse cultural and
linguistic backgrounds. While used in previous studies,
the included ratings had not been validated specifically
for our population, which is a general problem in refu-
gee health research. Hollifield et al. reviewed a range of
rating scales used in refugee health studies, some of
which were also used in the present study. They found
the HTQ and HSCL-25 to be fairly well-validated, but
found the majority of the remaining reviewed ratings
scales to be poorly validated for refugee groups [9].
However, in the present study, we found that Cronbach’s
alpha was high for the majority of the rating scales.
The study also holds important strengths. Unlike most
studies in the field, participants were randomised, which
reduces selection bias and improves comparability
between the two intervention groups. Furthermore, we
aimed to avoid restricting the inclusion unnecessarily in
order to make the patient group similar to the popula-
tion treated at other refugee health care facilities both in
Denmark and worldwide: refugee patients with substan-
tial comorbidity and multiple trauma-related disorders.
Notably, they are not “pure” PTSD patients and results
should be interpreted in light of this fact.
The study is a pragmatic trial, which means that we
investigated the drugs as they are used in a real life
setting. The disadvantage is that patients do not always
follow clinicians’ advice and guidelines, resulting in
non-optimal dosages of the investigated drugs and
discontinuation of treatment for a variety of reasons.
Consequently, the results in our study contribute to
our knowledge on the effects of sertraline and venlafax-
ine in the dosages that has been possible to achieve for
typical patients in a refugee healthcare setting – not the
drugs taken in maximum dosages in a controlled setting
with a carefully selected group of patients. An important
advantage of this approach is that the results and lessons
learned from this study are, to a large extent, transferrable
to similar refugee health facilities. The design is fairly
simple and manuals were used for all interventions, which
makes the study easy to replicate in similar or larger
settings.
Conclusion
In the present study, sertraline had a somewhat better
outcome than venlafaxine on several secondary out-
come measures, although no difference was found on
the primary outcome measure, the HTQ. As mentioned
above, this is in line with the findings of a similar study
conducted previously [19]. Although differences in the
effects of the two drugs were small and possibly due to
the low dosage of venlafaxine achieved, sertraline used in
a pragmatic clinical setting seems to be at least as good as
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venlafaxine and possibly better tolerated. Nonetheless, a
final conclusion on tolerability cannot be drawn based on
the data of the presented study alone.
The present study has brought new knowledge on the
effects of sertraline and venlafaxine in trauma-affected
refugees. Still, the drugs investigated are merely two out
of a range of psychotropis used in refugee mental health
settings. Hence, there is still an urgent need for large-
scale randomised studies of both trauma-affected refu-
gees and other PTSD populations in order to determine
the efficacy of other pharmacological agents typically
used in the field, for example TCAs, newer antidepres-
sants such as agomelatine, and other types of psychotro-
pics such as topiramate or prazozin.
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